32 results
Thumbnail

D1.103 - Two cases of discrepancy between fractional exhaled nitric oxide and airway eosinophils in asthma

Thumbnail

D1.104 - Severe Bronchial Asthma Phenotypes in a Referral Tertiary Center in Saudi Arabia

Thumbnail

D1.105 - Lichen Planus induced by treatment of severe eosinophilic asthma with biological therapy

Thumbnail

D1.106 - Grape polyphenols reduce the concentration of LPS in patients with asthma

Thumbnail

D1.107 - Polyphenol concentrate reduces CRP in asthma patients who have had COVID-19

Thumbnail

D1.108 - Grape polyphenols increase the concentration of BPI in asthma patients who have had SARS-CoV-2

Thumbnail

D1.109 - Predominance of eosinophilic pathogenetic mechanisms in a severe allergic asthma patient on biologic therapy

Thumbnail

D1.110 - Analysis of clinical and anamnestic risk factors of bronchial asthma in children

Thumbnail

D1.111 - Improving severe asthma through psychological management of traumatic life events

Thumbnail

D1.112 - Managing patients with Type 2 inflammation in a joint interdisciplinary “United Airways Clinic” at Lund University Hospital, Sweden

Thumbnail

D1.113 - Severe Asthma and Depression: the Overlooked Burden

Thumbnail

D1.114 - The Hidden Costs of Severe Asthma Treatment: Unveiling the Iatrogenic Burden

Thumbnail

D1.115 - Post-emergency asthma management

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results